Krystalenia Valasaki
Overview
Explore the profile of Krystalenia Valasaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
599
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atchaneeyasakul K, Valasaki K, Silvera R, Khan A, Yavagal D
Neurol Res
. 2024 Mar;
46(4):326-329.
PMID: 38468486
Background: Cell-based therapy has emerged as a promising avenue for post-stroke recovery. A significant challenge lies in tracking the distribution and engraftment of transplanted cells within the target cerebral tissue....
2.
Rieger A, Tompkins B, Natsumeda M, Florea V, Banerjee M, Rodriguez J, et al.
Stem Cells Transl Med
. 2022 May;
11(1):59-72.
PMID: 35641169
Background: Left ventricular hypertrophy and heart failure with preserved ejection fraction (HFpEF) are primary manifestations of the cardiorenal syndrome in patients with chronic kidney disease (CKD). Therapies that improve morbidity...
3.
Benny M, Courchia B, Shrager S, Sharma M, Chen P, Duara J, et al.
Stem Cells Transl Med
. 2022 Mar;
11(2):189-199.
PMID: 35298658
Bronchopulmonary dysplasia (BPD) is a life-threatening condition in preterm infants with few effective therapies. Mesenchymal stem or stromal cells (MSCs) are a promising therapeutic strategy for BPD. The ideal MSC...
4.
Khan A, Bellio M, Schulman I, Levi A, Longsomboon B, Brooks A, et al.
Front Cell Dev Biol
. 2021 Jun;
9:675738.
PMID: 34169074
The U.S. Food and Drug Administration (FDA) provides guidance for expanded access to experimental therapies, which in turn plays an important role in the Twenty-first Century Cures Act mandate to...
5.
Bolli R, Mitrani R, Hare J, Pepine C, Perin E, Willerson J, et al.
Eur J Heart Fail
. 2021 Apr;
23(4):661-674.
PMID: 33811444
Aims: CONCERT-HF is an NHLBI-sponsored, double-blind, placebo-controlled, Phase II trial designed to determine whether treatment with autologous bone marrow-derived mesenchymal stromal cells (MSCs) and c-kit positive cardiac cells (CPCs), given...
6.
Hatzistergos K, Durante M, Valasaki K, Wanschel A, Harbour J, Hare J
Sci Adv
. 2020 Dec;
6(49).
PMID: 33268364
The degree to which populations of cardiac progenitors (CPCs) persist in the postnatal heart remains a controversial issue in cardiobiology. To address this question, we conducted a spatiotemporally resolved analysis...
7.
Florea V, Rieger A, Natsumeda M, Tompkins B, Banerjee M, Schulman I, et al.
Cardiovasc Res
. 2020 Feb;
116(13):2131-2141.
PMID: 32053144
Aims: Sex differences impact the occurrence, presentation, prognosis, and response to therapy in heart disease. Particularly, the phenotypic presentation of patients with non-ischaemic dilated cardiomyopathy (NIDCM) differs between men and...
8.
Hatzistergos K, Jiang Z, Valasaki K, Takeuchi L, Balkan W, Atluri P, et al.
Stem Cells Dev
. 2018 Jan;
27(12):819-830.
PMID: 29336212
Microgravity-induced alterations in the autonomic nervous system (ANS) contribute to derangements in both the mechanical and electrophysiological function of the cardiovascular system, leading to severe symptoms in humans following space...
9.
Tompkins B, DiFede D, Khan A, Landin A, Schulman I, Pujol M, et al.
J Gerontol A Biol Sci Med Sci
. 2017 Oct;
72(11):1513-1522.
PMID: 28977399
Background: Aging frailty, characterized by decreased physical and immunological functioning, is associated with stem cell depletion. Human allogeneic mesenchymal stem cells (allo-hMSCs) exert immunomodulatory effects and promote tissue repair. Methods:...
10.
Florea V, Rieger A, DiFede D, El-Khorazaty J, Natsumeda M, Banerjee M, et al.
Circ Res
. 2017 Sep;
121(11):1279-1290.
PMID: 28923793
Rationale: Cell dose and concentration play crucial roles in phenotypic responses to cell-based therapy for heart failure. Objective: To compare the safety and efficacy of 2 doses of allogeneic bone...